Sinopharm Dongfeng General Hospital (Hubei Clinical Research Center of Hypertension), School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China.
Children's Medical Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Front Immunol. 2024 Sep 24;15:1462384. doi: 10.3389/fimmu.2024.1462384. eCollection 2024.
Type 1 diabetes mellitus (T1DM), a complex chronic disease with an intricate etiology and pathogenesis, involves the recognition of self-antigens by pancreatic islet autoantigen-specific T cells and plays crucial roles in both early- and late-stage destruction of beta cells, thus impacting disease progression. Antigen-specific T cells regulate and execute immune responses by recognizing particular antigens, playing broad roles in the treatment of various diseases. Immunotherapy targeting antigen-specific T cells holds promising potential as a targeted treatment approach. This review outlines the pathogenesis of diabetes, emphasizing the pivotal role of pancreatic islet autoantigen-specific T cells in the progression and treatment of T1DM. Exploring this avenue in research holds promise for identifying novel therapeutic targets for effectively managing diabetes.
1 型糖尿病(T1DM)是一种复杂的慢性疾病,具有复杂的病因和发病机制,涉及胰岛自身抗原特异性 T 细胞对自身抗原的识别,在β细胞的早期和晚期破坏中起关键作用,从而影响疾病的进展。抗原特异性 T 细胞通过识别特定抗原来调节和执行免疫应答,在治疗各种疾病中发挥广泛作用。针对抗原特异性 T 细胞的免疫疗法作为一种靶向治疗方法具有很大的潜力。本综述概述了糖尿病的发病机制,强调了胰岛自身抗原特异性 T 细胞在 T1DM 的进展和治疗中的关键作用。在研究中探索这一途径有望为有效管理糖尿病找到新的治疗靶点。